Home › Funds › ADAR1 Capital Management, LLC › DNLI
ADAR1 Capital Management, LLC position in DNLI
DENALI THERAPEUTICS INC · Health Care
ADAR1 Capital Management, LLC reported holding 1,029,080 shares of DNLI (DENALI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$26.5M, representing 1.47% of its reported portfolio and ranking #12 among its reported holdings. ADAR1 Capital Management, LLC has disclosed DNLI holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's DNLI position evolved
ADAR1 Capital Management, LLC first disclosed a stake in DNLI in Q1 2024 at 2,000 shares (US$41K). The position peaked in Q1 2026 at 1,871,455 shares, worth US$35.9M. Across 10 filings, ADAR1 Capital Management, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,029,080 shares valued at US$26.5M — a reduction of -842,375 shares quarter over quarter.. Notable position changes include a 1800% increase in Q2 2024 (shares rose 25% over the following quarter), a 168% increase in Q3 2024 (shares fell 30% over the following quarter), a 3491% increase in Q1 2026 (shares rose 34% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 2.00K | $41.04K | New |
| Q2 2024 | 38.00K | $882.36K | Add |
| Q3 2024 | 101.83K | $2.97M | Add |
| Q4 2024 | 44.83K | $913.55K | Reduce |
| Q1 2025 | 13.87K | $188.60K | Reduce |
| Q2 2025 | 35.72K | $499.67K | Add |
| Q3 2025 | 51.52K | $748.01K | Add |
| Q4 2025 | 52.12K | $860.43K | Add |
| Q1 2026 | 1.87M | $35.93M | Add |
| Q2 2026 | 1.03M | $26.47M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNLI and 13F data
DNLI (DENALI THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in DNLI — the largest reported positions include Temasek Holdings (US$180.4M), Temasek Holdings (Private) Ltd (US$180.4M), BAKER BROS. ADVISORS LP (US$96.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNLI
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Temasek Holdings (Private) Ltd 7.01M sh · $180.37M · Q2 2026
- BAKER BROS. ADVISORS LP 3.73M sh · $96.05M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Crestline Management, L.P. 1.91M sh · $49.14M · Q2 2026
- Foresite Capital Management VI LLC 1.40M sh · $35.92M · Q2 2026
- Siren, L.L.C. 1.40M sh · $35.92M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held DNLI?
ADAR1 Capital Management, LLC has disclosed DNLI holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is ADAR1 Capital Management, LLC's current position in DNLI?
As of Q2 2026, ADAR1 Capital Management, LLC holds 1.03M shares of DNLI (DENALI THERAPEUTICS INC), valued at $26.47M, representing 1.47% of its reported portfolio and ranking #12.
Has ADAR1 Capital Management, LLC been buying or selling DNLI?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in DNLI. The position peaked in Q1 2026 at 1.87M shares.
Which other funds hold DNLI?
Other major institutional holders of DNLI include Temasek Holdings, Temasek Holdings (Private) Ltd, BAKER BROS. ADVISORS LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.